ArticleJournal of medical physics
Evaluation of Interfraction Dose Discrepancies in Organs at Risk, Clinical Target Volume, and Points A and B in Computed Tomography-based High-dose-rate Intracavitary Brachytherapy for Cervical Cancer Patients.
Article in Journal of medical physics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: Brachytherapy is an integral part of the management of carcinoma cervix. High-dose-rate intracavitary brachytherapy (HDR ICBT) is often delivered after external beam radiotherapy (EBRT) in more than one session. The uncertainties may arise due to variations in anatomy and applicator position during each session, which may impact dose distribution to the clinical target volume (CTV) and normal organs. This study aims to quantify interfraction dose variations in HDR ICBT for cervical cancer patients using computed tomography-based planning. Materials and Methods: In this retrospective study, 30 patients with carcinoma cervix of the International Federation of Gynecology and Obstetrics stage IB2 to IVA after EBRT were included in the study. Total dose for ICBT was 21 Gy delivered in 3 weekly fractions. Doses to CTV, Point A, Point B, and normal organs (rectum, bladder, and sigmoid colon) were recorded in each session. Statistical analysis was conducted using the Chi-square test to compare dose variations between fractions, with a significance level set at Results: Mean dose received by 90% of the CTV was 5.92 Gy, 5.77 Gy, and 6.05 Gy for the first, second, and third fractions, respectively. Doses to 0.1 cc of bladder were 8.02 Gy, 7.17 Gy, and 7.51 Gy across fractions, whereas for 1 cc, doses were 6.17 Gy, 5.88 Gy, and 6.15 Gy, respectively. For 1 cc of rectum, doses were 5.60 Gy, 4.90 Gy, and 5.23 Gy, and for 2 cc, 5.17 Gy, 4.34 Gy, and 4.71 Gy, respectively, for three fractions. Sigmoid doses had relatively stable dose variation. Conclusion: Bladder, rectal, and sigmoid doses varied considerably across fractions, emphasizing the need for strict organ preparation protocols and adaptive dose monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.